InMed Pharmaceuticals grants CEO 1.56M options

Available on EDGAR 11/12/2026 - 04:31 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

InMed Pharmaceuticals Inc. (INM) reported that President and Chief Executive Officer Gregory J. Divis, who is also a director, received a stock-option award representing the right to purchase 1,560,599 common shares on November 9, 2026. The options vest 25% on November 9, 2027, then in equal monthly installments through November 9, 2030, subject to his continued service on each vesting date.

Insider Trade Summary

Grant/Award: 1,560,599 shares

Grant/Award 1 txn

Insider Divis Gregory J

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	1,560,599	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,560,599 options (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 1,560,599 options (Direct)

Footnotes (1)

1. F1. This option represents the right to purchase 1,560,599 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Key Figures

Stock-option award: 1,560,599 options Exercise price: $16 per share Initial vesting: 25% +1 more

4 metrics

Stock-option award 1,560,599 options Right to purchase common stock

Exercise price $16 per share Options awarded to Gregory J. Divis

Initial vesting 25% Vests on November 9, 2027, subject to continued service

Expiration date November 9, 2036 Option expiration

Key Terms

Stock Option (Right to Buy), vest

2 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest financial

"will vest as to 25% on November 9, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock-option award did INM CEO Gregory J. Divis receive?

On November 9, 2026, President and Chief Executive Officer and director Gregory J. Divis received an option award for 1,560,599 shares of common stock, with an exercise price of $16 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Divis Gregory J

(Last) (First) (Middle)

C/O MENTARI THERAPEUTICS, INC.

221 CRESCENT ST., BUILDING 23, SUITE 105

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ MTRI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$16	11/09/2026		A		1,560,599		(1)	11/09/2036	Common Stock	1,560,599	$0	1,560,599	D

Explanation of Responses:

1. This option represents the right to purchase 1,560,599 shares of the Issuer's common stock and will vest as to 25% on November 9, 2027 and in equal monthly installments thereafter through November 9, 2030, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

President and Chief Executive Officer

	/s/ Jerad G. Seurer, as attorney-in-fact for Gregory Divis	11/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)